Vita Life Sciences (VLS) investor relations material

Executive summary

• Achieved record half-year performance for the six months ended June 2026, with revenue up 6% to $48.3 million and profit before tax up 19% to $8.1 million, supported by broad-based growth and strong consumer sentiment.

• Net profit after tax increased 14.9% to $5.5 million year-over-year.

• Growth driven by improved operating margins, favorable product mix, disciplined cost management, and capital management.

Financial highlights

• Revenue rose 6% year-over-year to $48.3 million for the half year ended June 2026.

• Gross profit margin increased by 3 percentage points to 64% (reported as 63.5% in some sources).

• EBITDA grew to $8.2 million from $7.0 million, and EBIT increased to $7.7 million from $6.4 million year-over-year.

• Profit before tax up 19% to $8.1 million; profit after tax up to $5.5 million from $4.8 million.

• Basic EPS improved to 10.22 cents from 8.61 cents; half-year dividend increased to 5.0 cents per share.

Outlook and guidance

• Continued distribution expansion and targeted market initiatives in Australia, Malaysia, Singapore, and Vietnam.

• Revised China strategy with a new exclusive e-commerce distributor to be implemented in Q3 2026.

• Board will monitor economic uncertainties and provide further outlook in Q4.